Evidence map›Paper›PMID 41937949›Full record

ArticleDevice2026

A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer.

Aoibhin M Sheedy, Mihir Shetty, Anna Weis, Laura E Bendzick, Terran Stenger, Zhenya Ni, Philippa R Kennedy, Jacob A Myers, Niamh Ward, Lesley Trask and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Device, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Aoibhin M SheedyBiomedical Engineering, School of Engineering, College of Science and Engineering, University of Galway, Galway, Ireland.
Mihir ShettyMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Anna WeisMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Laura E BendzickMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Terran StengerMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Zhenya NiMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Philippa R KennedyMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Jacob A MyersMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Niamh WardBiomedical Engineering, School of Engineering, College of Science and Engineering, University of Galway, Galway, Ireland.
Lesley TraskBiomedical Engineering, School of Engineering, College of Science and Engineering, University of Galway, Galway, Ireland.
Hannah PrendevilleBiomedical Engineering, School of Engineering, College of Science and Engineering, University of Galway, Galway, Ireland.
Joanne O'DwyerBiomedical Engineering, School of Engineering, College of Science and Engineering, University of Galway, Galway, Ireland.
Michael O'DwyerApoptosis Research Centre, University of Galway, Galway, Ireland.
Ellen T RocheCÚRAM, Centre for Research in Medical Devices, University of Galway, Galway, Ireland.
Garry P DuffyCÚRAM, Centre for Research in Medical Devices, University of Galway, Galway, Ireland.
Jeffrey S MillerMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Melissa A GellerMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Eimear B DolanBiomedical Engineering, School of Engineering, College of Science and Engineering, University of Galway, Galway, Ireland.
Martin FelicesMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.

Funding

Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
Targeting off-the-shelf iPSC-derived natural killer cells against solid tumorsR35CA283892 · NCI · UNIVERSITY OF MINNESOTA · PI Jeffrey S. Miller · 2023 to 2026
$3.7M
NCI NIH HHS P01 CA111412NCI NIH HHS R35 CA283892
6 · The paper itself

Abstract

Intraperitoneal (i.p.) therapy improves outcomes in abdominal cancers but remains underutilized due to complications from repurposed catheters. In this work, we present a replenishable therapeutic implant for repeated, localized delivery of therapies to the peritoneal cavity. In an ovarian cancer mouse model, expanded natural killer (eNK) cells were delivered once weekly and interleukin-15 (IL-15) thrice weekly. This regime reduced tumor burden compared to standard i.p. injection. The implant supports co-administration of chemotherapy, cytokines, monoclonal antibodies, or other protein-based therapies. Negative pressure applied via the port enabled longitudinal sampling of peritoneal fluid without additional surgical intervention. By reducing procedural burden and improving adaptability, the implant can help increase patient retention and therapeutic efficacy in ovarian cancer and other intra-abdominal cancers.

Identifiers

PMID41937949
PMCPMC13048345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.